AOD-9604
Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
FDA Status
Not FDA-approved — Category 1 (compounding allowed)
Typical Dose
250–500 mcg daily (subcutaneous)
Evidence Grade
C+Preclinical evidence + anecdotal clinical use
Clinics Indexed
134 providers have offered AOD-9604 in our tracked directory.
Key Reported Benefits
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade C+ indicates preclinical evidence + anecdotal clinical use.
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 1 (compounding allowed)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
Related Peptides
Semaglutide
A+A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
Tirzepatide
A+A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
Tesamorelin
AAn FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.